Tuberculosis
Conditions
Keywords
tuberculosis, rdESAT-6, CFP-10, skin test, diagnostic test
Brief summary
Tuberculosis (TB) continues to be the most important bacterial infection worldwide and therefore new improved diagnostic tests are needed to help doctors in diagnosing TB. The new skin test is named C-Tb. Like the current Tuberculin Skin Test (TST), the C-Tb test is injected just under the skin and will when positive show a redness and/or swelling at the injection site while a negative test will leave no reactions. The aim of this trial is to test the C-Tb skin test in adults diagnosed with TB to determine if a TB infected individual has a truly positive test result (this is called to find the sensitivity of the skin test).
Detailed description
The trial is designed to investigate the sensitivity of C-Tb using various sizes of cut-off of induration in a double blind randomised, split-body study comparing 0.1 µg/0.1 mL C-Tb with the reference agent 2 T.U. Tuberculin PPD RT23 SSI. (Each volunteer receives the C-Tb agent in one arm and 2 T.U. Tuberculin PPD RT 23 SSI in the other arm). Two groups of adult patients recently diagnosed with active TB will be investigated; patients in the main group will NOT have a co-infection with HIV and patients in the second group will have a co-infection with HIV. The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme. The primary objectives are to assess the sensitivity of the C-Tb test as a function of the cut-off value (i.e., the smallest size of induration measured in mm resulting in a positive outcome of the C-Tb test) when the test is administered intradermally by the Mantoux technique to HIV negative adult patients recently diagnosed with active TB and to assess the sensitivity of the C-Tb test as a function of the cut-off value (i.e., the smallest size of induration measured in mm resulting in a positive outcome of the C-Tb test) when the test is administered intradermally by the Mantoux technique to HIV positive adult patients recently diagnosed with active TB The sensitivity is defined as the relative frequency of patients with an induration response ≥ cut-off in TB patients. Similarly the specificity of the C-Tb test is defined as the relative frequency of subjects in a healthy population (i.e., no exposure to M. tuberculosis) who have an induration response \< cut-off after a C-Tb test. An optimal cut-off point of being infected will be determined by combing the results from the present sensitivity study with those from a parallel specificity study in (BCG vaccinated) individuals with no previous exposure to M. tuberculosis. The secondary objectives of the trial is to compare the induration response of C-Tb with the induration response of 2 T.U. Tuberculin PPD RT 23 SSI, to compare the induration response of C-Tb with the in-vitro IFN-γ response measured at screening using the QuantiFERON®-TB Gold In Tube assay, to correlate the induration response to the initial CD4+ counts in HIV positive patients and to record all adverse events (local and systemic) occurring within 28 days after application of the agents
Interventions
BIOLOGICALC-Tb
The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
BIOLOGICAL2 TU Tuberculin PPD RT 23 SSI
The 2 TU Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
Sponsors
Statens Serum Institut
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
(HIV negative patients): 1. Has signed an informed consent 2. Aged 18 to 65 years 3. Has been diagnosed with active TB: 1. has a compatible clinical picture of TB according to South African guidelines with the intention to treat and at least 1 documented positive sputum smear microscopy result or 2. has a compatible clinical picture of TB according to South African Guidelines with the intention to treat and a positive culture result 4. Is HIV negative confirmed by 2 two rapid tests (Abbott-DetermineTM HIV-1/2 and Sensa (Seyama Solutions, SA)) 5. Is willing and likely to comply with the trial procedures 6. Is prepared to grant authorized persons access to their medical record Inclusion Criteria (HIV positive patients): 1. Has signed an informed consent 2. Aged 18 to 65 years 3. Has a compatible clinical picture of TB according to South African guidelines with the intention to treat 4. Is HIV positive confirmed by: 1. 2 positive rapid tests (Abbott-DetermineTM HIV-1/2 and Sensa (Seyama Solutions, SA)) or 2. 1 positive rapid tests (Abbott-DetermineTM HIV-1/2 or Sensa (Seyama Solutions, SA)) and an additional confirmatory ELISA (Enzygnost anti-HIV-1/2 Plus) 5. Is willing and likely to comply with the trial procedures 6. Is prepared to grant authorized persons access to their medical records
Exclusion criteria
1. Has been in treatment for TB for more than 2 weeks 2. Has a known MDR/XDR-TB 3. Has within 3 months prior to the day of inclusion been in treatment with a product which is likely to modify the immune response except for HIV treatment (e.g., immunoglobulin, systemic corticosteroids, methotrexate, azathioprine, cyclosporine or blood products) 4. Has been vaccinated with a live vaccine within 6 weeks prior to the day of inclusion (e.g. MMR, yellow fever, oral typhoid vaccines) 5. Has been vaccinated with BCG \< 6 months prior to the day of inclusion 6. Has been tuberculin (TST) tested \< 6 months prior to the day of inclusion 7. Has an active disease affecting the lymphoid organs except for HIV (e.g., Hodgkin's disease, lymphoma, leukaemia, sarcoidosis) 8. Has a current skin condition which interferes with the reading of the skin tests e.g. tattoos, severe scarring, burns/sunburns, rash, eczema, psoriasis, or any other skin disease at or near the injection sites 9. Has a condition where blood drawings pose more than minimal risk for the patient, such as haemophilia, other coagulation disorders, or significantly impaired venous access 10. Currently participating in another clinical trial with an investigational or non investigational drug or device, or has participated in another clinical trial within the 3 months prior to dosing 11. Has participated in previous clinical trials investigating the ESAT-6 and/or CFP-10 antigens 12. Is pregnant, breastfeeding or intending to get pregnant 13. Has a condition which in the opinion of the investigator is not suitable for participation in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The diameter of induration at the injection sites measured transversely to the long axis of the forearm 2-3 days after application of the agents | From injections to 2-3 days after aplication |
Secondary
| Measure | Time frame |
|---|---|
| Injection site adverse reactions within 28 days after application of the agents | Onset between the injections and 28 days after the injections |
| All adverse events occurring within 28 days after application of the agents | Onset between the injections and 28 days after the injections |
| Laboratory safety parameters of haematology and biochemistry | Onset between the injections and 28 days after the injections |
| In vitro IFN-γ response as measured by the QuantiFERON®-TB Gold In Tube assay | Onset between the injections and 28 days after the injections |
Countries
South Africa
Outcome results
None listed